Novel Cryptigen technology unlocks full potential of Tumour Specific Antigens CAMBRIDGE, England and MONTREAL, April 25, 2022 /PRNewswire/ Epitopea, a transatlantic cancer immunotherapeutics
/PRNewswire/ Epitopea, a transatlantic cancer immunotherapeutics company and global leader in exploiting a new class of untapped tumour-specific antigens.